Factor 13 A (G39) Peptide 
Datasheet
COA
MSDS
SHIP
Product Name :
Factor 13 A (G39) Peptide Applications :
Blocking Background :
Hemostasis following tissue injury involves the deployment of essential plasma procoagulants (prothrombin, and factors V, VIII, IX and X), which are involved in a blood coagulation cascade leading to the formation of insoluble fibrin clots and the promotion of platelet aggregation. Coagulation factor VII (serum prothrombin conversion accelerator, proconvertin, F7, Factor VII) is a 406 amino acid, vitamin K-dependent, single chain serine protease that is synthesized in the liver and circulates as an inactive precursor. Factor IXa, factor Xa, factor XIIa, or thrombin mediated proteolytic cleavage of Factor VII at Arg152-Ile153 generates Factor VIIa, an active serine protease composed of a catalytic heavy chain disulfide linked to a light chain, containing two EGF-like domains. Coagulation factor XIII is a terminal effector in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of two A subunits and two B subunits. The A subunits have catalytic function, and the noncatalytic B subunits may serve as plasma carrier molecules. Alternative Name :
Coagulation factor XIII A chain; Coagulation factor XIIIa; Protein-glutamine gamma-glutamyltransferase A chain; Transglutaminase A chain; F13A1; F13A; factor13 Swiss-Prot :
P00488 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide Factor 13 A (G39). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS7027 Factor 13 A (G39) pAb.
Factor 13 A (G39) Peptide Applications :
Blocking Background :
Hemostasis following tissue injury involves the deployment of essential plasma procoagulants (prothrombin, and factors V, VIII, IX and X), which are involved in a blood coagulation cascade leading to the formation of insoluble fibrin clots and the promotion of platelet aggregation. Coagulation factor VII (serum prothrombin conversion accelerator, proconvertin, F7, Factor VII) is a 406 amino acid, vitamin K-dependent, single chain serine protease that is synthesized in the liver and circulates as an inactive precursor. Factor IXa, factor Xa, factor XIIa, or thrombin mediated proteolytic cleavage of Factor VII at Arg152-Ile153 generates Factor VIIa, an active serine protease composed of a catalytic heavy chain disulfide linked to a light chain, containing two EGF-like domains. Coagulation factor XIII is a terminal effector in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of two A subunits and two B subunits. The A subunits have catalytic function, and the noncatalytic B subunits may serve as plasma carrier molecules. Alternative Name :
Coagulation factor XIII A chain; Coagulation factor XIIIa; Protein-glutamine gamma-glutamyltransferase A chain; Transglutaminase A chain; F13A1; F13A; factor13 Swiss-Prot :
P00488 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide Factor 13 A (G39). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS7027 Factor 13 A (G39) pAb.
Blocking peptide available as BS7027PP